Congenital muscular dystrophy associated with merosin deficiency
- PMID: 8807418
- DOI: 10.1177/088307389601100406
Congenital muscular dystrophy associated with merosin deficiency
Abstract
"Classic" congenital muscular dystrophy is a heterogeneous group of disorders, characterized by early-onset muscle weakness and hypotonia, absence of overt cerebral or ocular symptoms, and muscle pathology consistent with a dystrophic process. A subset of patients with congenital muscular dystrophy have recently been found to be deficient in the extracellular matrix protein merosin. Consequently, we reviewed the clinical, pathologic, and immunohistochemical features of 12 patients (six males and six females) with classic congenital muscular dystrophy who have been seen at the Children's Hospital, Boston, over the past 15 years. There was marked clinical heterogeneity within this patient population, with age of independent ambulation ranging from 13 months to 6 years. Immunocytochemical analysis using antibodies to merosin, dystrophin, 43-kDa dystroglycan, adhalin, and laminin was normal in 11 of 12 patients. One patient had markedly abnormal staining for merosin; the majority of fibers were negative, although occasional fibers demonstrated patchy staining. Immunoblot analysis in this patient demonstrated markedly reduced levels of merosin (< 10% compared to controls and other patient), of apparently normal size. Clinically, this patient could be differentiated from the others by a marked elevation of serum creatine kinase (> 1000 U/L) and the presence of early white-matter changes on magnetic resonance imaging. The results of this study support the observation that abnormalities of merosin are present in a subgroup of patients with classic congenital muscular dystrophy. Although marked elevation of serum creatine kinase and white-matter changes on magnetic resonance imaging may serve to distinguish these patients from other patients with congenital muscular dystrophy, there remains a large proportion of patients in whom the underlying pathogenesis remains to be elucidated.
Similar articles
-
The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review.J Med Genet. 2001 Oct;38(10):649-57. doi: 10.1136/jmg.38.10.649. J Med Genet. 2001. PMID: 11584042 Free PMC article. Review.
-
Merosin-deficient congenital muscular dystrophy type 1A.Rom J Morphol Embryol. 2008;49(2):229-33. Rom J Morphol Embryol. 2008. PMID: 18516331
-
Congenital muscular dystrophy syndromes distinguished by alkaline and acid phosphatase, merosin, and dystrophin staining.Neurology. 1996 Mar;46(3):810-14. doi: 10.1212/wnl.46.3.810. Neurology. 1996. PMID: 8618688
-
Clinical phenotype in congenital muscular dystrophy: correlation with expression of merosin in skeletal muscle.Neuromuscul Disord. 1995 Jul;5(4):301-5. doi: 10.1016/0960-8966(94)00069-l. Neuromuscul Disord. 1995. PMID: 7580243
-
[Non-Fukuyama type congenital muscular dystrophy--merosin deficient and positive forms].Nihon Rinsho. 1997 Dec;55(12):3176-80. Nihon Rinsho. 1997. PMID: 9436431 Review. Japanese.
Cited by
-
Human laminin-111 and laminin-211 protein therapy prevents muscle disease progression in an immunodeficient mouse model of LAMA2-CMD.Skelet Muscle. 2020 Jun 4;10(1):18. doi: 10.1186/s13395-020-00235-4. Skelet Muscle. 2020. PMID: 32498713 Free PMC article.
-
The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review.J Med Genet. 2001 Oct;38(10):649-57. doi: 10.1136/jmg.38.10.649. J Med Genet. 2001. PMID: 11584042 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous